/ EXPERT INSIGHTSCould Excess Cortisol Be Driving Type 2 Diabetes Resistance? by Niall O'Donnell, PhDManaging Director of RiverVestVenture PartnersWhy taming a stress hormone might be the next breakthrough in type 2 diabetes care(September 24, 2025) - Millions of people on type 2 diabetes (T2B) regimens do...
Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility? ...
Learn how Alleviant's no-implant approach addresses the full spectrum of chronic heart failure....
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
For this Expert Insight, RiverVest spoke with Vikram Sudarsan, PhD, founder and CEO of Engrail Therapeutics about the significant unmet need for safer, more effective treatments for anxiety disorders and how the company's lead drug candidate, ENX-102, is addressing that need....
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation. ...
In this article, Managing Director Tom Melzer breaks down RiverVest's investment strategy, which centers on managing risk and capital efficiency with one goal in mind: a successful and profitable exit that will maximize investor return. ...